{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:20Z","timestamp":1792794680177,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University of Utah Matheson Center for Health Care Studies","id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"crossref"}]},{"name":"University of Utah Clinical & Translational Science Institute"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UM1TR004409-01"],"award-info":[{"award-number":["1UM1TR004409-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, several new treatment regimens have been approved for treating metastatic hormone-sensitive prostate cancer, building on androgen deprivation therapy alone. These include docetaxel androgen deprivation therapy, abiraterone acetate-prednisone androgen deprivation therapy, apalutamide androgen deprivation therapy, enzalutamide androgen deprivation therapy, darolutamide-docetaxel androgen deprivation therapy, and abiraterone-prednisone androgen deprivation therapy with docetaxel. There are no validated predictive biomarkers for choosing a specific regimen. The goal of this study was to conduct a health economic outcome evaluation to determine the optimal treatment from the US public sector (Veterans Affairs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a partitioned survival model in which metastatic hormone-sensitive prostate cancer patients transitioned between 3 health states (progression free, progressive disease to castrate resistance state, and death) at monthly intervals based on Weibull survival model estimated from published Kaplan\u2013Meier curves using a Bayesian network meta-analysis of 7 clinical trials (7208 patients). The effectiveness outcome in our model was quality-adjusted life-years (QALYs). Cost input parameters included initial and subsequent treatment costs and costs for terminal care and for managing grade 3 or higher drug-related adverse events and were obtained from the Federal Supply Schedule and published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Average 10-year costs ranged from $34\u200a349 (androgen deprivation therapy) to $658\u200a928 (darolutamide-docetaxel androgen deprivation therapy) and mean QALYs ranged from 3.25 (androgen deprivation therapy) to 4.57 (enzalutamide androgen deprivation therapy). Treatment strategies docetaxel androgen deprivation therapy, enzalutamide androgen deprivation therapy docetaxel, apalutamide androgen deprivation therapy, and darolutamide-docetaxel androgen deprivation therapy were eliminated because of dominance (ie, they were more costly and less effective than other strategies). Of the remaining strategies, abiraterone acetate-prednisone androgen deprivation therapy was the most cost-effective strategy at a willingness-to-pay threshold of $100\u200a000\/QALY (incremental cost-effectiveness ratios = $21\u200a247\/QALY).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our simulation model found abiraterone acetate-prednisone androgen deprivation therapy to be an optimal first-line treatment for metastatic hormone-sensitive prostate cancer from a public (Veterans Affairs) payer perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djad135","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T09:28:22Z","timestamp":1689067702000},"page":"1374-1382","source":"Crossref","is-referenced-by-count":23,"title":["Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective"],"prefix":"10.1093","volume":"115","author":[{"given":"Minkyoung","family":"Yoo","sequence":"first","affiliation":[{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah (UT) School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Nelson","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah (UT) School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haaland","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of UT , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Department of Economics, University of UT , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A","family":"Cutshall","sequence":"additional","affiliation":[{"name":"University of UT School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Kohli","sequence":"additional","affiliation":[{"name":"Case Western Reserve University , Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rylee","family":"Beckstead","sequence":"additional","affiliation":[{"name":"School of Medicine, University of UT , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6614","authenticated-orcid":false,"given":"Manish","family":"Kohli","sequence":"additional","affiliation":[{"name":"Division of Oncology-Department of Medicine, University of UT\/Huntsman Cancer Institute , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"1","key":"2023111012325104700_djad135-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J Clin"},{"issue":"3","key":"2023111012325104700_djad135-B2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2023111012325104700_djad135-B3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2023111012325104700_djad135-B4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2023111012325104700_djad135-B5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10323","key":"2023111012325104700_djad135-B6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"2023111012325104700_djad135-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2023111012325104700_djad135-B8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023111012325104700_djad135-B9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"10336","key":"2023111012325104700_djad135-B10","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2023111012325104700_djad135-B11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2023111012325104700_djad135-B12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"2023111012325104700_djad135-B13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","article-title":"Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: a meta-analysis","volume":"173","author":"Ciccarese","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"2023111012325104700_djad135-B14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.urols.2017.10.001","article-title":"Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer - the urologists\u2019 perspective","volume":"28","author":"Tan","year":"2017","journal-title":"Urol Sci"},{"issue":"24","key":"2023111012325104700_djad135-B15","first-page":"2345","article-title":"Darolutamide in metastatic prostate cancer. Reply","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2023111012325104700_djad135-B16","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"2023111012325104700_djad135-B17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","article-title":"Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes","volume":"38","author":"Smare","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"2023111012325104700_djad135-B18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s41669-021-00263-w","article-title":"Onwards and upwards: a systematic survey of economic evaluation methods in oncology","volume":"5","author":"Ball","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"15","key":"2023111012325104700_djad135-B19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"2023111012325104700_djad135-B20","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"9747","key":"2023111012325104700_djad135-B21","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"2023111012325104700_djad135-B22","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"383","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2023111012325104700_djad135-B23","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2023111012325104700_djad135-B24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2023111012325104700_djad135-B25","author":"Rohatgi"},{"key":"2023111012325104700_djad135-B26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2023111012325104700_djad135-B27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"6","key":"2023111012325104700_djad135-B28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/13696998.2019.1584109","article-title":"Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis","volume":"22","author":"Costanzo","year":"2019","journal-title":"J Med Econ"},{"issue":"5","key":"2023111012325104700_djad135-B29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.25122\/jml-2021-0361","article-title":"The economic burden of stroke: a systematic review of cost of illness studies","volume":"14","author":"Strilciuc","year":"2021","journal-title":"J Med Life"},{"issue":"9","key":"2023111012325104700_djad135-B30","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/CCM.0000000000004451","article-title":"Trends, cost, and mortality from sepsis after trauma in the United States: an evaluation of the national inpatient sample of hospitalizations, 2012-2016","volume":"48","author":"Eguia","year":"2020","journal-title":"Crit. Care Med"},{"issue":"1","key":"2023111012325104700_djad135-B31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/JOM.0b013e31820290f4","article-title":"The direct and indirect cost burden of acute coronary syndrome","volume":"53","author":"Johnston","year":"2011","journal-title":"J Occup Environ Med"},{"issue":"2","key":"2023111012325104700_djad135-B32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12788\/jhm.2683","article-title":"Cost of acute kidney injury in hospitalized patients","volume":"12","author":"Silver","year":"2017","journal-title":"J Hosp Med"},{"issue":"2","key":"2023111012325104700_djad135-B33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40273-013-0121-y","article-title":"The economic burden of skeletal-related events among elderly men with metastatic prostate cancer","volume":"32","author":"Jayasekera","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2023111012325104700_djad135-B34","first-page":"163","article-title":"Budget impact of enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"22","author":"Bui","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2023111012325104700_djad135-B35","author":"Perrin","year":"2014"},{"issue":"4","key":"2023111012325104700_djad135-B36","first-page":"335","article-title":"The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma","volume":"24","author":"Swallow","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2023111012325104700_djad135-B37","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benef"},{"issue":"2","key":"2023111012325104700_djad135-B38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023111012325104700_djad135-B39","doi-asserted-by":"crossref","first-page":"e64275","DOI":"10.1371\/journal.pone.0064275","article-title":"Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis","volume":"8","author":"Zhong","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"2023111012325104700_djad135-B40","first-page":"E126","article-title":"A cost-utility analysis of apalutamide for metastatic castration sensitive prostate cancer","volume":"16","author":"Parmar","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"2023111012325104700_djad135-B41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13696998.2022.2066850","article-title":"Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada","volume":"25","author":"Saad","year":"2022","journal-title":"J Med Econ"},{"issue":"10","key":"2023111012325104700_djad135-B42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.urolonc.2019.05.017","article-title":"Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer","volume":"37","author":"Ramamurthy","year":"2019","journal-title":"Urol Oncol"},{"issue":"1","key":"2023111012325104700_djad135-B43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jnci\/dju366","article-title":"Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data","volume":"107","author":"Heijnsdijk","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2023111012325104700_djad135-B44","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5489\/cuaj.5889","article-title":"Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer","volume":"13","author":"Beca","year":"2019","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"2023111012325104700_djad135-B45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jval.2011.04.008","article-title":"Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib","volume":"14","author":"Casciano","year":"2011","journal-title":"Value Health"},{"key":"2023111012325104700_djad135-B46","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"11","key":"2023111012325104700_djad135-B47","doi-asserted-by":"crossref","first-page":"e0277282","DOI":"10.1371\/journal.pone.0277282","article-title":"Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer","volume":"17","author":"Barbier","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"2023111012325104700_djad135-B48","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2021.10.016","article-title":"Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: an economic evaluation based on network meta-analysis","volume":"25","author":"Wang","year":"2022","journal-title":"Value Health"},{"issue":"2","key":"2023111012325104700_djad135-B49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023111012325104700_djad135-B50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djad135\/51032887\/djad135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/11\/1374\/52934456\/djad135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/11\/1374\/52934456\/djad135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T07:34:40Z","timestamp":1699601680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/115\/11\/1374\/7223200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,7,12]]},"published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djad135","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,7,12]]}}}